1 citations
,
March 2024 in “Pathogens” Beau's lines on nails may indicate severe COVID-19 or vaccination response.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
9 citations
,
July 2021 in “Essays in Biochemistry” Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.
91 citations
,
May 2020 in “Monaldi Archives for Chest Disease” Understanding gender differences in COVID-19 is crucial for effective health strategies.
9 citations
,
January 2020 in “Critical Reviews in Immunology” MAIT cells may help fight COVID-19 but also contribute to severe inflammation.
2 citations
,
May 2025 in “Frontiers in Epidemiology” Standardized definitions and better methods are needed to accurately estimate long COVID-19 prevalence.
November 2025 in “Preprints.org” New-onset fibromyalgia after COVID-19 is poorly understood and needs more research.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
Antiandrogens might help prevent or treat COVID-19 by blocking the virus's entry into cells.
25 citations
,
June 2023 in “Biomedicines” Men generally face more severe COVID-19 outcomes than women, partly due to hormonal differences.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
17 citations
,
January 2023 in “Frontiers in Cell and Developmental Biology” iPSCs are promising for studying and treating COVID-19.
13 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.
1 citations
,
October 2025 in “Biology of Sex Differences” Gender and social factors, not just biology, affect COVID-19 death rates.
February 2024 in “PubMed” More people experience hair loss after recovering from COVID-19 in hospitals than in outpatient settings.
10 citations
,
December 2020 in “Frontiers in Medicine” Men are more at risk for severe COVID-19 due to biological differences, suggesting the need for targeted treatments.
July 2025 in “The Korean Journal of Internal Medicine” Certain immune responses may cause ongoing COVID-19 symptoms like fatigue and brain fog.
9 citations
,
June 2023 in “Human Genomics” MX1 and AR genes are linked to milder COVID-19, while TMPRSS2 increases severe risk, especially in women.
September 2025 in “International Journal of Emergency Medicine” More skin issues appeared in the emergency department during COVID-19, highlighting the need for better dermatology training and resources.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
4 citations
,
June 2022 in “Journal of food bioactives” Eating plant-based anti-inflammatories and antioxidants may help manage long-term COVID-19 health issues.
52 citations
,
August 2021 in “Microorganisms” Higher ACE2 levels in certain tissues may worsen COVID-19 in people with other health issues, especially older adults.
17 citations
,
May 2022 in “Frontiers in Immunology” Reprogramming macrophages to resolve inflammation can help reduce severe COVID-19 complications.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
14 citations
,
April 2022 in “Molecules” Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.
22 citations
,
September 2021 in “Journal of Personalized Medicine” The pandemic worsened physical and mental challenges for women with PCOS.
8 citations
,
August 2022 in “Microorganisms” A standardized drug development platform is essential for efficient and effective drug repurposing, especially during pandemics.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
1 citations
,
January 2024 in “Microorganisms” Mice with a virus similar to COVID-19 had skin damage, but a special treatment helped repair it.
113 citations
,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.